Autopsy report · NCT02817347

A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea

“Sponsor's decision for the Drug Development.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 10 months before it stopped.
• 135 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Yuhan Corporation

Sponsor type

Industry

Conditions

Otitis Media; Otorrhea

Interventions

piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%; piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%; piperacillin 2% + tazobactam 0.25%; piperacillin 4% + tazobactam 0.5%; piperacillin 8% + tazobactam 1.0%

Participants

135

Sites

1

Countries

South Korea

Trials that died the same way

• Prospective Longitudinal Monocentric Study to Evaluate the Syde® Digital Endpoint in Patients With Multiple Sclerosis
  “Sponsor's decision” (76% match in meaning)
• A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer
  “Sponsor decision.” (76% match in meaning)
• Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia
  “Sponsor decision following FDA release from the PMR.” (76% match in meaning)
• The Effect of a Probiotic Strain on Aspirin-induced GI Damage
  “Decision made by Sponsor” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.